资源描述
2023 iResearch Inc.2 ABSTRACTS APP+/3 CONTENTS01 Overview02 Value exploration04 Case study05 Reflection and appeal03 Market development4 Overview015 2023.9 iResearch I 3.0 1.0 2.0 ai 3.0 1.0 2.0 3.0 6 2023.9 iResearch I Digital Therapeutics Alliance DTA Digital therapeutics DTx DTx DTx DTA 5 APP 7 2023.9 iResearch I DTx DTx(RCT)DTA DTx DTx DTx DTA/8 2023.9 iResearch I 1/3/+9 2023.9 iResearch I 2/3 APP APP APP APP+AI/APP 10 2023.9 iResearch I 3/3 IBT/11 2023.9 iResearch I DTx DTx 2022 DTA/+/+/Pear reSET Somryst+my PKFiT+Freespira PTSD 12 Value exploration0213 2023.9 iResearch I+WHO 2020 IDF 2022 65 14%22 115 85 2021 1.4 3 2 WHO 5400 8.7%/2021 76845 GDP 6.72%10 215.6%60%24346 31669409755259865841768454.99%5.34%5.95%6.32%6.67%6.72%2011 2013 2015 2017 2019 2021 GDP%2009-2021 14 2023.9 iResearch I DTx DTx DTx XR+XR VR AR MR 15 2023.9 iResearch I 1/4)DTA 16 2023.9 iResearch I 2/4)+DTA 1 2 3 17 2023.9 iResearch I 3/4)&18 2023.9 iResearch I 4/4)DTA 1231 3 2 19Market development0320 2023.9 iResearch I DTx DTx DTx DTx DTx 2020 DTx BfArM DTx DTx 2020 DTx DTx DTx 2020 BfArM DTx DTx BfArM DTx DTx DTx DTx DTx DTx 21 2023.9 iResearch I Dtx DTx DTx DTx H C DTx DTx 25102021 2022 2023 Q1 2021-2023Q1 37132023 2021 13 DTx 2022 3 2023 Q1 DTx 22 2023.9 iResearch I C DTx C DTx B2C 1 DTx 2 B2I DTx B2H/DTx DTx DTx DTx B2B DTx/B2P DTx DTx+DTx B2G 23 2023.9 iResearch I DTx DTx DTx logo DTx DTxCDMO DTx DTx DTx 24 2023.9 iResearch I logo 25 2023.9 iResearch I DTx DTx DTx 2022 DTx,26 2023.9 iResearch I22333344444610111417 DTx 2023 8 95 DTx 9 DTx 72%DTx DTx 2022 IT 25.0%21.0%14.0%12.0%10.0%10.0%4.0%3.0%1.0%2021 2023 1111111111111 27 2023.9 iResearch I DTx WHO 2022 DTx DTx DTx DTx AR/VR AR/VR AR/VR 2022 10 8 1 71%2022 5400 28 40%2022 3300 60 AD 983 30%2022 12%1600 28 2023.9 iResearch I DTx 5G 1 2 3 4 1 DTx DTx 2 DTx 3 DTx 4 DTx 5G DTx DTx-DTx DTx 29 2023.9 iResearch I 2023 8 22 DTx DTx DTx DTx VR 1 DTx Step1 Step2 Step3 DTx 2 1 DTx 2 DTx VR 3 DTx 3 1 VR+DTx VR DTx 2 DTx DTx 30 Case study0431 2023.9 iResearch I NMPA AI IIT SaaS AI RWS 32 2023.9 iResearch I 2023 8 8-33 2023.9 iResearch I-VR 3D 1000 6 8 172 216 1772 VR Cabor AI+34Reflection and appeal0535 2023.9 iResearch I DTx DTx DTx APP DTx DTx DTx DTx DTx DTx DTx 36 2023.9 iResearch I DTx DTx 60 DTx DTx DTx“DTx DTx DTx DTx DTx DTx DTx DTx DTx 37 2023.9 iResearch I DTx 2C 2I 2B 2G DTx DTx DTx DTx 2C 2C DTx 2B DTx DTx DTx 2H DTx DTx 2I DTx DTx 2G DTx DTx 38 2023.9 iResearch I DTx DTx DTx DTx DTx DTx DTx DTx DTx DTx DTx DTx DTx DTx DTx 39 2023.9 iResearch I DTx DTx CRO/CXO DTx DTx DTx DTx DTx DTx DTx DTx CRO CXO 40 2023.9 iResearch I DTx DTx DTx DTx DTx DTx DTx DTx DTx+DTx DTx DTx DTx DTx DTx+41 2023.9 iResearch I 42BUSINESS COOPERATION 400-026-43LEGAL STATEMENT THANKS
展开阅读全文